<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593047</url>
  </required_header>
  <id_info>
    <org_study_id>KBT004</org_study_id>
    <secondary_id>2007-004413-33</secondary_id>
    <nct_id>NCT00593047</nct_id>
  </id_info>
  <brief_title>LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin</brief_title>
  <official_title>A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Statin Treatment in Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karo Bio AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karo Bio AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid hormones are known to reduce cholesterol levels through regulation of a number of key&#xD;
      enzymes involved in synthesis, degradation, and lipid transport. However, the currently&#xD;
      marketed thyroid agonists are non-selective, and cannot be used for the treatment of&#xD;
      hypercholesterolemia due to extrahepatic consequences of hyperthyroidism, especially on&#xD;
      heart, bone, and muscle.&#xD;
&#xD;
      To take advantage of thyroid hormone effect on lipid metabolism for the treatment of&#xD;
      hypercholesterolemia, it is necessary to develop a selective thyroid receptor agonist that&#xD;
      can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the&#xD;
      extrahepatic tissue. KB2115 is a thyroid agonist developed to be liver selective.&#xD;
&#xD;
      The purpose of the study is to assess the efficacy and safety of KB2115 as add on therapy to&#xD;
      low and middle doses of statin following 12 weeks of exposure compared to placebo. The aim of&#xD;
      the study is to assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115 at&#xD;
      doses between 25 and 100 µg and to define a clinically relevant dose or dose range for future&#xD;
      studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Statin + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Statin + KB2115 dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Statin + KB2115 dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Statin + KB2115 dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KB2115</intervention_name>
    <description>tablet formulation given once daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Males or females aged 18 to 75 years. Female patients must be non-fertile. To be&#xD;
             considered as non-fertile, females must fulfil the following:&#xD;
&#xD;
               -  Non-nursing and non-pregnant 12 months prior to enrolment&#xD;
&#xD;
               -  Not of child bearing potential ie, either documented irreversible surgically&#xD;
                  sterile (bilateral oophorectomy or hysterectomy is acceptable, but not tubal&#xD;
                  ligation) or post-menopausal. Post-menopausal is defined as serum&#xD;
                  follicle-stimulating hormone (FSH) levels in the post-menopausal range combined&#xD;
                  with amenorrhea for more than 1 year in a woman above 50 years of age, or&#xD;
                  amenorrhea for more than 2 years below 50 years of age&#xD;
&#xD;
          3. Patients with hypercholesterolemia treated with stable doses of the below listed lipid&#xD;
             lowering medication for at least 3 months prior to randomization&#xD;
&#xD;
               -  Atorvastatin not more than 20 mg/day or&#xD;
&#xD;
               -  Simvastatin not more than 40 mg/day&#xD;
&#xD;
          4. LDL-cholesterol &gt; 3.0 mmol/L (Week -1)&#xD;
&#xD;
          5. Subject able and willing to comply with all study requirements&#xD;
&#xD;
          6. At randomization, diet as instructed by the investigator during the last 4 weeks prior&#xD;
             to randomization and willingness to follow these instructions throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cholesterol lowering agents other than the defined statins&#xD;
&#xD;
          2. History of somatic or psychiatric disease/condition, which may interfere with the&#xD;
             objectives of the study as judged by the investigator&#xD;
&#xD;
          3. Clinically significant illness or clinically relevant trauma within 2 weeks before the&#xD;
             administration of the investigational product as judged by the investigator&#xD;
&#xD;
          4. Chronic (&gt; 3 months) pain condition requiring daily medication with pain killers&#xD;
&#xD;
          5. Glycosylated haemoglobin (HbA1c) &gt; 7.0%&#xD;
&#xD;
          6. Diabetes requiring medication other than metformin&#xD;
&#xD;
          7. Clinically abnormal physical findings and laboratory values as judged by the&#xD;
             investigator and abnormal resting ECG, eg, QTc interval &gt; 450 msec&#xD;
&#xD;
          8. Body Mass Index of ≥ 40 kg/m2&#xD;
&#xD;
          9. Resent history (&lt; 3 month) of stroke or transient ischemic attacks&#xD;
&#xD;
         10. History of seizure disorder, except febrile convulsions&#xD;
&#xD;
         11. A current diagnosis of cancer, unless in remission&#xD;
&#xD;
         12. Blood pressure (BP) of &gt; 160/95 mm Hg&#xD;
&#xD;
         13. History of cardiac arrhythmia, such as intermittent supraventricular tachyarrhythmia&#xD;
             and atrial fibrillation&#xD;
&#xD;
         14. Unstable angina pectoris, myocardial infarction or coronary bypass graft surgery or&#xD;
             percutaneous coronary intervention &lt; 6 month before randomization&#xD;
&#xD;
         15. Congestive heart failure New York Heart Association Class &gt; 2&#xD;
&#xD;
         16. Unstable or severe angina pectoris or peripheral artery disease&#xD;
&#xD;
         17. Known thyroid disease or thyroid biomarkers (TSH, T3, free T3, T4, free T4) outside&#xD;
             reference range for normal at enrolment and at baseline&#xD;
&#xD;
         18. Positive urine pregnancy test in women at enrolment&#xD;
&#xD;
         19. Use of thyroid replacement therapy and hormone replacement therapy (including&#xD;
             contraceptive pills) for last 3 months before randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kristensen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karo Bio AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carl-Peter Anderberg</name>
      <address>
        <city>Gothemburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <last_update_submitted>November 27, 2008</last_update_submitted>
  <last_update_submitted_qc>November 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Jens Kristensen, Chief Medical Officer</name_title>
    <organization>Karo Bio AB</organization>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

